Does oxytocin augmentation increase perinatal risk in primigravid labor?

Area of Science:

• Obstetrics and Gynecology
• Perinatal Medicine
• Reproductive Health

Background:

• Oxytocin is commonly used to augment labor.
• Concerns exist regarding high-dose oxytocin's safety in spontaneous labor.
• Active management of labor aims to prevent prolonged labor and adverse outcomes.

Purpose of the Study:

• To evaluate the safety of high-dose oxytocin augmentation in spontaneous labor.
• To assess the influence of oxytocin on adverse perinatal outcomes in primigravid deliveries.
• To determine if oxytocin use is associated with increased risks such as neonatal seizures or death.

Main Methods:

• Retrospective analysis of 30,874 primigravid term deliveries.
• Comparison of perinatal outcomes between oxytocin-treated and non-oxytocin-treated groups.
• Inclusion of data on asphyxial perinatal death, neonatal seizures, and abnormal neonatal neurologic behavior.

Main Results:

• Oxytocin augmentation (45% of cases) did not significantly increase adverse perinatal outcomes.
• Despite a longer mean labor duration in the oxytocin group, rates of asphyxial death, neonatal seizures, and abnormal neurologic behavior were not elevated.
• No cases of uterine rupture were reported in any primigravid labor during the study period.

Conclusions:

• High-dose oxytocin augmentation of spontaneous labor is associated with maternal and fetal safety.
• Oxytocin can be safely used in active labor management protocols for dystocia in primigravid women.
• Clinical practice over 13 years supports the safety of oxytocin for correcting labor dystocia when progress fails.